VEGFA and nonpapillary renal cell carcinoma: Moreover, available efficient treatment was required apart from vascular endothelial growth factor (VEGF) pathway kinase inhibitors (sorafenib and sunitinib) and rapamycin (mTOR) blockers, which are now the first and second line therapies for late stage and metastatic ccRCC [17].